Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis
- PMID: 14674938
- DOI: 10.1046/j.1398-9995.2003.00129.x
Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis
Abstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) is characterized by a heightened Th2 CD4+ T-cell response to Aspergillus fumigatus allergens and a hyper-immunoglobulin (Ig)E state compared with cystic fibrosis patients without ABPA. We hypothesize that one reason for this response is increased sensitivity to interleukin (IL)-4 in ABPA resulting in increased expression of CD23 and CD86 and leading to a positive amplification mechanism that increases Th2 CD4+ T cell responses.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from seven ABPA CF and 19 non-ABPA CF patients and 16 nonatopic controls and stimulated with rIL-4 (range 0.1-10 ng/ml) and rIL-13 (range 1-10 ng/ml) for 48 h. The number of CD23 molecules and percentages of CD23+ B cells were quantified by flow cytometry. Both phorbol 12-myristate 13-acetate (PMA)/ionomycin (IO) and antigen stimulated, toxoid and Asp f2/f3/f4, PBMC were examined for cytoplasmic cytokine synthesis enumerated by cytokine staining using flow cytometry to measure Th2 and Th1 CD3+ T cells.
Results: The numbers of CD23 molecules on B-cells were significantly elevated at time 0 in ABPA CF patients compared with both non-ABPA CF patients and nonatopic controls. Following IL-4 stimulation in vitro, the numbers and percentages of CD23 expression on B cells were significantly up-regulated in ABPA CF patients compared with non-ABPA CF patients and controls. The IL-13 stimulation up-regulated CD23 expression; however, there was no significant difference in ABPA CF patients compared with non-ABPA CF patients and controls. The percentages of interferon (IFN)-gamma+ CD3+T cells following PMA/IO stimulation were significantly decreased in both ABPA and non-ABPA CF patients compared with controls. There were no significant differences of IL-4+ and IL-13+ CD3+ T cells between ABPA and non-ABPA CF patients. When tetanus toxoid stimulated T cells were examined, both ABPA and non-ABPA CF patients had significantly decreased IFN-gamma+ CD3+ T cells compared with controls. In Asp f2/f3/f4 stimulated T cells, ABPA CF patients had significantly increased IL-4+ CD3+ T cells compared with non-ABPA CF patients and controls.
Conclusions: ABPA CF patients have increased sensitivity to IL-4 but not to IL-13 up-regulation of CD23 molecules compared with non-ABPA CF patients. There were decreased percentages of IFN-gamma+ and IL-2+ Th1 T cells in CF patients compared with nonatopic controls but similar percentages of IL-4+ Th2 T cells in all three groups. However, ABPA CF patients had increased frequency of Aspergillus-stimulated Th2 T cells. This indicated that there is skewing of Th2 T cells in ABPA CF patients. Thus, in CF ABPA patients there is increased Th2 T cells and increased sensitivity to IL-4.
Similar articles
-
Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis.Int Arch Allergy Immunol. 2000 Dec;123(4):319-26. doi: 10.1159/000053644. Int Arch Allergy Immunol. 2000. PMID: 11146389
-
IgE antibody to Aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis.Allergy. 2004 Feb;59(2):198-203. doi: 10.1046/j.1398-9995.2003.00310.x. Allergy. 2004. PMID: 14763934
-
Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis.Pediatr Pulmonol. 1999 Feb;27(2):74-9. doi: 10.1002/(sici)1099-0496(199902)27:2<74::aid-ppul2>3.0.co;2-l. Pediatr Pulmonol. 1999. PMID: 10088929
-
Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis.J Cyst Fibros. 2002 Jun;1(2):76-89. doi: 10.1016/s1569-1993(02)00033-4. J Cyst Fibros. 2002. PMID: 15463812 Review.
-
Allergic bronchopulmonary mycosis complicating cystic fibrosis.Semin Respir Infect. 1992 Sep;7(3):179-92. Semin Respir Infect. 1992. PMID: 1475542 Review.
Cited by
-
Gene therapy for cystic fibrosis.Clin Rev Allergy Immunol. 2008 Dec;35(3):164-78. doi: 10.1007/s12016-008-8080-3. Clin Rev Allergy Immunol. 2008. PMID: 18600482 Review.
-
Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis.Clin Dev Immunol. 2011;2011:843763. doi: 10.1155/2011/843763. Epub 2011 Apr 5. Clin Dev Immunol. 2011. PMID: 21603163 Free PMC article. Review.
-
Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab.Intern Med. 2021 Sep 1;60(17):2839-2842. doi: 10.2169/internalmedicine.6679-20. Epub 2021 Mar 1. Intern Med. 2021. PMID: 33642487 Free PMC article.
-
Host-pathogen interplay in the respiratory environment of cystic fibrosis.J Cyst Fibros. 2015 Jul;14(4):431-439. doi: 10.1016/j.jcf.2015.02.008. Epub 2015 Mar 19. J Cyst Fibros. 2015. PMID: 25800687 Free PMC article. Review.
-
Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series.J Allergy Clin Immunol Pract. 2020 Feb;8(2):742-743. doi: 10.1016/j.jaip.2019.11.031. Epub 2019 Dec 4. J Allergy Clin Immunol Pract. 2020. PMID: 31811944 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous